Condensed Consolidated Statements Of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012	Mar. 31, 2011
Revenues:
Collaborative research and development	$ 158	$ 56	$ 1,823	$ 218
Royalty income	380	304	1,004	1,032
Total revenues	538	360	2,827	1,250
Operating expenses:
Research and development	1,508	1,737	5,629	5,013
General and administrative	1,757	1,762	5,269	5,932
Impairment of intangible assets			14,830
Total operating expenses	3,265	3,499	25,728	10,945
Loss from operations	(2,727)	(3,139)	(22,901)	(9,695)
Other income (expense):
Change in fair value of derivatives		334	170	1,130
Interest income	10	7	30	19
Other income (expense), net	1		(1)	(11)
Total other income	11	341	199	1,138
Loss before income taxes	(2,716)	(2,798)	(22,702)	(8,557)
Income tax benefit	30	113	129	69
Net loss	$ (2,686)	$ (2,685)	$ (22,573)	$ (8,488)
Basic and diluted net loss per share:	$ (0.13)	$ (0.13)	$ (1.09)	$ (0.45)
Weighted average common shares outstanding:
Basic and diluted	20,803	20,177	20,787	19,072